Showing papers in "Journal of Cardiac Failure in 2006"

TL;DR: Heart failure is a syndrome characterized by high mortality, frequent hospitalization, reduced quality of life, and a complex therapeutic regimen that makes HF an ideal candidate for practice guidelines.

TL;DR: Chronic infusion of GLP-1 significantly improves left ventricular function, functional status, and quality of life in patients with severe heart failure.

TL;DR: Age at initial presentation, ratio of NC/C, and number of affected segments seem to be major determinants of LV systolic dysfunction, while initial LVEF and last functional capacity predict mortality in this cohort.

TL;DR: Though women are treated less aggressively, treatment gaps exists in both sexes, and length of stay and in-hospital mortality rates are similar, more women than men are hospitalized with ADHF.

TL;DR: A high prevalence of anxiety is found in the HF outpatient population and depression and social isolation predicted mortality independent of demographic and clinical status in HF outpatients.

TL;DR: In this article, the authors summarize and integrate insights derived from a multitude of studies that have investigated how LVAD support influences ventricular structural, cellular, extracellular matrix, molecular, biochemical, and metabolic characteristics of the end-stage failing heart.

TL;DR: DMPs have the potential to reduce morbidity and mortality for patients with CHF and the benefit of the intervention depends on age, severity of disease, guideline-based treatment at baseline, and DMP modalities.

TL;DR: Although disease management is effective in the mainstream HF patient population, in Hispanics this ill, elderly, and poorly educated, a different approach may be needed.

TL;DR: A very simple questionnaire measuring social network can identify patients with a higher short-term risk of hospital readmission, and this association was comparable to that of other important predictors of readmissions, such as previous hospitalization.

TL;DR: CoQ10 enhances systolic function in chronic heart failure, but its effectiveness may be reduced with concomitant use of current standard therapies.

TL;DR: Substantial proportion of the variation in the effects of heart failure on patients' quality of life as measured by the MLHF score can vary with age independently of symptoms, and pathologic measures including ejection fraction and B-type natriuretic peptide are not strongly related to symptom assessments.

TL;DR: It is suggested that exercise test responses, non-exercise test estimates of physical function, and quality of life indices reflect different facets of health status in HF and one should not be considered a surrogate for another.

TL;DR: The results of the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction study should help guide the selection of optimum antithrombotic therapy for patients with left ventricular dysfunction.

TL;DR: Inhibition of XO by oxypurinol in patients with CHF decreases SUA and improves LVEF and improves cardiac function in Patients with LVEf < or = 40% after 1 month of treatment.

TL;DR: Using multivariate analysis, MMP-9 levels were the only circulating factor predictive of late onset CHF and may hold prognostic significance in MI patients.

TL;DR: The stereotypic cardiomyopathy and disease progression in the characterized, high-expressing transgenic strain suggests its utility as a model to study the effects of pharmacologic or genetic manipulations in heart failure.

TL;DR: Hospitalized HF patients are increasingly elderly, have a greater prevalence of diseases that lead to renal dysfunction, and have more severe renal dysfunction and anemia on admission, however, adjusting for these secular trends in patient characteristics, mortality after HF admission is improving.

TL;DR: Among heart failure outpatients, difficulty taking medications is associated with worse health status, and this association appears to be explained, in part, by coexistent depression.

TL;DR: Anti-HCV antibodies were identifiable in sera stored for 13 to 17 years and were more prevalent in patients with myocarditis and HF than in the general population.

TL;DR: Myocardial FFA metabolism is reduced in patients with idiopathic dilated cardiomyopathy, however, when LV function is further depressed and insulin resistance manifested, myocardian FFA uptake and oxidation are, in turn, upregulated.

TL;DR: NPSDs are associated with increased risk of death, CVD, progressive HF death, SCD, and HF hospitalization and a randomized trial is needed to assess the role of NPSDs versus PSDs in HF patients.

TL;DR: Although men and women perceived similar barriers to following the sodium-restricted diet, women were more adherent to the SRD and had greater knowledge about following an SRD.

TL;DR: The changes in myocardial GRK2 expression and activity that are mirrored in lymphocytes provide a possible mechanism for the restoration of betaAR signaling and reverse remodeling after mechanical unloading in the failing heart.

TL;DR: Proteomics studies can provide new insights into molecular mechanisms in CHF and phosphorylated small HSPs may be involved in preventing cardiac dysfunction.

TL;DR: Wider use of this simple nongeometric parameter may help to identify patients for whom options for further intervention should be carefully evaluated, and RV dysfunction, as assessed by the RV MPI, is associated with adverse outcome.

TL;DR: Improvements in LV global function, dyssynchrony variables and symptoms in patients chronically paced from the RV that are similar to those observed in patients with LBBB without preexisting devices are suggested.

TL;DR: In this very high-risk, advanced HF population, 45% of patients developed worsening renal function during UF therapy and controlled studies are needed to determine the impact of UF on renal function and outcomes in high- risk populations such as this.

TL;DR: Higher cystatin C concentrations are strongly associated with left ventricular hypertrophy and diastolic dysfunction in outpatients with coronary artery disease and without heart failure.

TL;DR: In this article, the authors address the practical aspects of the decision to implant an implantable cardioverter-defibrillator (ICD) for primary prevention of sudden death in patients with symptomatic heart failure and reduced left ventricular ejection fraction, based on a distillation of recent trial experience.